[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644277":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":25,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":25,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":25,"overallStatus":58,"whyStopped":25,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":25},{"fullName":5,"class":6},"Pakistan Institute of Medical Sciences","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Risperidone","EXPERIMENTAL","Oral Risperidone 2-6 mg\u002Fday. Dose titrated based on clinical response and tolerability over 6 weeks. Administered once daily.'",[13],"Drug: Risperidone",{"label":15,"type":16,"description":17,"interventionNames":18},"Cariprazine","ACTIVE_COMPARATOR","Oral Cariprazine 1.5-6 mg\u002Fday,dose will be titrated based on clinical response",[19],"Drug: Cariprazine",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Oral Risperidone tablets, 2-6 mg\u002Fday administered once daily for 6 weeks. Dose titrated based on clinical response and tolerability. Approved antipsychotic for acute mania.'",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Oral Cariprazine capsules, 1.5-6 mg\u002Fday administered once daily for 6 weeks. Dose titrated based on clinical response and tolerability. Approved antipsychotic for acute mania",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Maera Hussain","CONTACT","+92-3160886631","maerahussain802@gmail.com",{"type":36,"investigatorFullName":31,"investigatorTitle":37,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Resident psychiatrist Pims","100644277","phase-4-risperidone-vs-cariprazine-in-acute-mania-100644277",false,"NCT07665073","Risperidone vs Cariprazine in Acute Mania","Risperidone vs Cariprazine in Acute Mania a Head to Head Comparison of Efficacy vs Tolerability","RCAM","Inclusion Criteria:\n\npatients with bipolar mania Age 18-60 YMRS\\>20 -\n\nExclusion Criteria:\n\nPatients with substance use Patients already taking antipsychotics Secondary mood disorder\n\n\\-","ALL","18 Years","60 Years",{"count":50,"type":51},50,"ESTIMATED","INTERVENTIONAL",[54],"PHASE4","Randomized, double-blind, parallel-group study comparing efficacy and safety of Risperidone versus Cariprazine in adults with acute manic episodes. Participants will receive oral study drug for 6 weeks. Primary outcome is change in YMRS total score from baseline to week 6.",[57],"Bipolar 1 Disorder","NOT_YET_RECRUITING","2026-06-18",{"date":61,"type":62},"2026-06-24","ACTUAL",{"date":64,"type":51},"2027-06",{"date":66,"type":51},"2028-06",{"name":5,"class":6}]